The short version of Aib substitution fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-13. Anything still debated is marked as such rather than presented as settled.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
A particular challenge in analysing AlphaFold models is distinguishing genuine topology from structural prediction artefacts. A high confidence score does not by itself guarantee that a predicted chain crossing is correct, and incorrect modelling of termini or flexible regions may change the calculated topology. AlphaKnot 2.0 therefore provides several measures intended to help evaluate a predicted knot, including the pLDDT values of the complete chain and knot core, the confidence near the boundaries of the knot core, and detection of unusually close contacts between Cα atoms. Users can also compare AlphaFold predictions with independently generated ESMFold models for shorter proteins. Because automated analysis at the scale of the AlphaFold database cannot be manually verified structure by structure, AlphaKnot 2.0 introduced a user annotation system. Database entries can be assessed by users as a knot, artifact, or unsure, allowing potentially incorrect predictions to be flagged for further consideration.
Tranexamic acid is a medication used to treat or prevent excessive blood loss from major trauma, postpartum bleeding, surgery, tooth removal, nosebleeds, and heavy menstruation. It is also used for hereditary angioedema. It is taken either by mouth, injection into a vein, or by intramuscular injection. Tranexamic acid is a synthetic analog of the amino acid lysine. It serves as an antifibrinolytic by reversibly binding four to five lysine receptor sites on plasminogen. This decreases the conversion of plasminogen to plasmin, preventing fibrin degradation and preserving the framework of fibrin's matrix structure. Tranexamic acid has roughly eight times the antifibrinolytic activity of an older analogue, ε-aminocaproic acid. Tranexamic acid also directly inhibits the activity of plasmin with weak potency (IC50 = 87 mM), and it can block the active-site of urokinase plasminogen activator (uPA) with high specificity (Ki = 2 mM), one of the highest among all the serine proteases. Side effects are rare; they include changes in color vision, seizures, blood clots, and allergic reactions. Tranexamic acid appears to be safe for use during pregnancy and breastfeeding. Tranexamic acid was first made in 1962 by Japanese researchers Shosuke and Utako Okamoto. It is on the World Health Organization's List of Essential Medicines. Tranexamic acid is available as a generic drug.
Alyx Vance is a fictional character from Valve's Half-Life video game series. She is introduced as a non-playable, supporting character in Half-Life 2 (2004), accompanying the player's character, Gordon Freeman, throughout much of the game. She subsequently appears in a similar capacity in Half-Life 2: Episode One (2006) and Episode Two (2007), and as the titular protagonist of the VR game Half-Life: Alyx (2020). Alyx is portrayed as a young woman in her mid-twenties of Afro-Asian descent, and is a prominent figure in the human resistance against the rule of the alien empire called the Combine and their human representative, Dr. Wallace Breen. She is the daughter of resistance leader Dr. Eli Vance, and becomes a close friend and ally of Gordon. She received highly positive reviews from critics.
=== Carcinogenicity === According to European Medicines Agency, formulations of trimebutine might be contaminated with N-nitrosamines. However, it was assigned CPCA Category 5 with acceptable daily intake of 1500 ng/day.
=== Notable faculty === Emily Anderson - first professor of German Nicholas Canny - historian Colm McDonald - professor of psychiatry Michael D. Higgins - sociologist, 9th President of Ireland William King - geologist Alice Perry - engineer Gerard Quinn - jurist, specialist in international and comparative disability law and policy Niamh Reilly - sociologist and political scientist George Johnstone Stoney - physicist
Sources: en.wikipedia.org
Parenteral nutrition (PN), or intravenous feeding, is the feeding of nutritional products to a person intravenously, bypassing the usual process of eating and digestion. The products are made by pharmaceutical compounding entities or standard pharmaceutical companies. The person receives a nutritional mix according to a formula including glucose, salts, amino acids, lipids, vitamins, and dietary minerals. It is called total parenteral nutrition (TPN) or total nutrient admixture (TNA) when no significant nutrition is obtained by other routes, and partial parenteral nutrition (PPN) when nutrition is also partially enteric. It is called peripheral parenteral nutrition (PPN) when administered through vein access in a limb rather than through a central vein as in central venous nutrition (CVN).
Moscow is one of the largest centers for science in Russia. The headquarters of the Russian Academy of Sciences are located in the city, as well as research and applied science institutions. Moscow also contains the following institutions:
== Pathology == The interaction of GPX4 with the autophagic degradation pathway further modulates cell's response to oxidative stress. Impaired GPX4 function plays a role in tumorigenesis, neurodegeneration, infertility, inflammation, immune disorders, and ischemia-reperfusion injury. Additionally, the R152H mutation in GPX4 is involved in the development of Sedaghatian-type spinal metaphyseal dysplasia, a rare and fatal disease in newborn babies.
==== MeSH E05.478.588 – immunohistochemistry ==== MeSH E05.478.588.375 – fluorescent antibody technique MeSH E05.478.588.375.050 – antibody-coated bacteria test, urinary MeSH E05.478.588.375.300 – fluorescent antibody technique, direct MeSH E05.478.588.375.310 – fluorescent antibody technique, indirect MeSH E05.478.588.375.341 – fluoroimmunoassay MeSH E05.478.588.375.341.350 – fluorescence polarization immunoassay MeSH E05.478.588.400 – immunoenzyme techniques MeSH E05.478.588.400.170 – enzyme-linked immunosorbent assay MeSH E05.478.588.400.180 – enzyme multiplied immunoassay technique
Sources: en.wikipedia.org
=== Secondary packaging === Secondary packaging contains a number of primary packages into one box, being made usually out of corrugated cardboard. Thus, the secondary level is a physical distribution carrier for the primary packages, making them more easy to handle during transportation. Occasionally, it can be used as an aid in retail outlets or supermarkets for the display of basic goods.
These strains are tested in laboratories to determine a strain's vigor, sulfur dioxide and alcohol tolerance, production levels of acetic acid and sulfur compounds, ability to re-ferment (positive for sparkling wine but a negative attribute for sweet late-harvest wines), development of surface film on the wine (positive for some Sherry styles but a negative attribute for many other wines), enhancement of a wine's color or certain varietal characteristics by enzymes in the yeast cells and other metabolic products produced by the yeast, foaming and flocculation tendencies, yeasticidal properties (a trait known as "Killer yeast") and tolerance for nutritional deficiencies in a must that may lead to a stuck fermentation.
The siliceous frustules of diatoms accumulate in fresh and brackish wetlands and lakes. Some peats and mucks contain a sufficient abundance of frustules such that they can be mined. Most of Florida's diatomaceous earths have been found in the muck of wetlands or lakes. The American Diatomite Corporation, from 1935 to 1946, refined a maximum of 145 tons per year from their processing plant near Clermont, Florida. Muck from several locations in Lake County, Florida was dried and burned (calcined) to produce the diatomaceous earth. It was formerly extracted from Lake Mývatn in Iceland. The commercial deposits of diatomite are restricted to Tertiary or Quaternary periods. Older deposits from as early as the Cretaceous Period are known, but are of low quality. Diatomite deposits rich in fossils have been located in New Zealand, but mining of the Foulden Maar deposits on an industrial scale, for conversion to animal feed, has drawn strong opposition.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.